This second in a two-part series describes how the resilience of a global vaccine network shaped clinical supply is challenged up to the last mile: at clinical sites.
- Building Resilient Clinical Supply Chains To Keep Trials On Track
- Randomization And Trial Supply Management (RTSM) Systems: Meet Your Neighbor Again
- Real-World Data Is Reshaping How We Supply Clinical Trials — And It's About Time
- Why Good Data Still Fails: Inconsistency, Visibility, And Decision Risk
- Designing CNS Trial Supply Chains: A Technical Framework
- Primary Healthcare Disruption And Clinical Trial Supply Risk
- Protecting Clinical Trials From Global Supply Disruptions
- From Passive To Predictive: The New Era Of Clinical Cold Chain Management
ON-DEMAND WEBINARS
Watch as industry experts explore the advancements in drug accountability facilitated through IRT, encompassing innovative methods for managing site variations and sustainable supply chains.
See how study characteristics, regulatory landscapes, and business priorities combine to inform clinical supply placement decisions between EU and non-EU European locations.
Experts take you through the entire selection process for primary packaging components for lyophilization and provide aspects to consider for all relevant attributes.
With so many moving parts in a clinical trial, why worry about the technology that is supposed to help manage it? In this webinar, explore five actionable and necessary strategies to leverage RTSM to simplify clinical trial operations.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1026593952 tablet, data]( "RTSM/IRT In Clinical Trials: The Complete Guide")
RTSM/IRT In Clinical Trials: The Complete GuideRTSM/IRT systems are essential to modern clinical trials. This guide explores how to implement and optimize them to boost efficiency, streamline operations, uphold study integrity, and ensure compliance.
-
![GettyImages-1253545551-OSD-pill-tablet-oral-solid-dose]( "Development And Manufacture Of A Highly Potent OSD Product")
Development And Manufacture Of A Highly Potent OSD ProductHighly potent drug compounds require advanced containment and robust technical transfer protocols. CDMOs overcome challenges through meticulous testing, specialized tooling, and strong supplier relationships.
-
![GettyImages-1404941712-Capsules_Blister_Packaging]( "Gain Confidence In Clinical Trial Outcomes")
Gain Confidence In Clinical Trial OutcomesDelve into the ways that smart packaging integrations within clinical trial strategies can improve adherence to dosing protocols and provide a comprehensive understanding of a patient’s exposure.
-
![Pharma Manufacturing GettyImages-1135140594]( "Outsourcing Your Highly Potent Oncology Drug Product")
Outsourcing Your Highly Potent Oncology Drug ProductPrecision oncology treatments require specialized manufacturing and packaging, leading companies to outsource production. Assessing a CDMO’s highly potent processing capabilities is critical.
-
![GettyImages-980809416 clinical supply]( "Consolidating Clinical Supply Chain Operations With GxP Inventory")
Consolidating Clinical Supply Chain Operations With GxP InventoryA Japan-based biotechnology company leveraged Signant SmartSignals® GxP Inventory, which improved visibility, reduced risks and costs, and optimized operations in this case study.
-
![IRT Getty 1407865352]( "How Modern Software Architecture Is Revolutionizing IRT Solutions")
How Modern Software Architecture Is Revolutionizing IRT SolutionsExplore the ways technology suppliers across the clinical trial space have begun investing in IRTs built around a microservices model capable of improving data access and visibility.
-
![GettyImages-1070902452-planning-tracking-packaging-shipment]( "Optimizing IRT For Clinical Supply Management")
Optimizing IRT For Clinical Supply ManagementExperts speak on supply capabilities within interactive response technology (IRT) – how flexibility is important to functionality and who to involve and which questions to ask in optimizing IRT for clinical supply.
-
![BO 2 - GC_App_^CZ vial with stopper and seal stack up]( "Bringing A Biosimilar For Oncology To Market: Injectable Packaging From Early Development To Commercialization")
Bringing A Biosimilar For Oncology To Market: Injectable Packaging From Early Development To CommercializationWhile in their early-stage development of a mAb biosimilar for oncology treatment, a large biopharmaceuticals company sought a packaging recommendation: a stopper to maintain high-quality standards.
-
![GettyImages-2036497698 clinical lab]( "Solutions For Sponsors Utilizing Drafted Guidance For PROs In Oncology")
Solutions For Sponsors Utilizing Drafted Guidance For PROs In OncologyExplore the challenges pharmaceutical companies face in implementing PROs in cancer clinical trials as outlined in the FDA’s draft guidance, as well as strategies to overcome these obstacles.
-
![gettyimages-871704288-170667a]( "The Patient-Centric Clinical Supply Chain For Cell And Gene Therapies")
The Patient-Centric Clinical Supply Chain For Cell And Gene TherapiesThis article explores how delivering cell and gene therapies to patients requires new levels of agility, flexibility and innovation in the logistical management of supply.
CATALENT CORNER
| Insights from Catalent's Clinical Supply Experts |
SPONSORED CONTENT
Impact Of Supplier Choice On APAC Clinical Trial Execution
Learn about strategies Asia-Pacific has become an increasingly complex and congested destination for clinical trials as local and global sponsors alike flock to the region to take advantage of its many benefits, including access to large patient pools. Choosing the right clinical packaging and supply chain partner to support these studies is critical and can vary significantly based upon what countries are involved and the types of services required.
